# Innovent Biologics

Suzhou-based innovator of domestic PD-1 inhibitors and biosimilars, exporting oncology biologics under accelerated NMPA pathways.


Source: https://en.bioecon.ru/companies/innovent-biologics/
Updated: 2026-07-29

- Country: China

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | Upfront payment of US$1.2 billion and US$350 million from collaborations with Takeda and Eli Lilly, respectively | https://www.hkexnews.hk/listedco/listconews/sehk/2026/0428/2026042805171.pdf |
| Capacity | 140,000 liters total operational capacity | https://en.innoventbio.com/InvestorsAndMedia/PressReleaseDetail?key=584, https://investor.innoventbio.com/media/1343/innovent-2025-annual-results_for-website.pdf, https://www.hkexnews.hk/listedco/listconews/sehk/2026/0428/2026042805171.pdf, https://www.prnewswire.com/news-releases/innovent-announces-2026-interim-results-and-business-updates-302859305.html |
| Certification | EMA Good Manufacturing Practice (GMP) certificate for Suzhou manufacturing site | https://www.hkexnews.hk/listedco/listconews/sehk/2026/0428/2026042805171.pdf, https://www.prnewswire.com/news-releases/innovent-announces-2026-interim-results-and-business-updates-302859305.html |
| Regulatory approval | 18 approved products in China as of April 2026 | https://www.hkexnews.hk/listedco/listconews/sehk/2026/0428/2026042805171.pdf |
| Production site | Suzhou (antibody and ADC capacity) and Hangzhou (antibody capacity) | https://investor.innoventbio.com/media/1343/innovent-2025-annual-results_for-website.pdf, https://www.hkexnews.hk/listedco/listconews/sehk/2026/0428/2026042805171.pdf, https://www.prnewswire.com/news-releases/innovent-announces-2026-interim-results-and-business-updates-302859305.html |
| Headcount | Approximately 9,000 employees worldwide (as of August 2026) | https://stockanalysis.com/quote/hkg/1801/employees/, https://www.prnewswire.com/news-releases/innovent-announces-2026-interim-results-and-business-updates-302859305.html |
| Revenue | RMB 8.6 billion total revenue in the first half of 2026 | https://www.prnewswire.com/news-releases/innovent-announces-2026-interim-results-and-business-updates-302859305.html |

Independent sources: en.innoventbio.com, hkexnews.hk, investor.innoventbio.com, prnewswire.com, stockanalysis.com

## Technologies

- [Biopharmaceuticals & biomedicines](https://en.bioecon.ru/technology/biopharmaceuticals-biomedicines/)